Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide

Anticancer Research

Volumn 28, Issue 1 A, 2008, Pages 1-8

  Frizelle, Sandra P ^b   Kratzke, Marian G ^b   Carreon, Richard R ^b   Engel, Sean C ^b   Youngquist, Laura ^b   Klein, Mark A ^a   Fourre, Laura ^b   Shekels, Laurie L ^a,b   Kratzke, Robert A ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cyclin dependent kinase; Mesothelioma; p16INK4a

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TRANSACTIVATOR PROTEIN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; MESOTHELIOMA; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 40549094291     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Antman KH, Pass HI and Recht A: Benign and malignant mesothelioma. In: DeVita VT, Hellman S and Rosenberg SA (eds.). Cancer: Principle and Practices of Oncology, 3rd edition. Philadelphia. J B Lippincot pp. 1399-1417, 1989.
2. INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87(24): 1870-1875, 1995.
3. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade E, Buckler AJ and Testa JR: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54: 5547-5551, 1994.
4. Xiao S, Li D, Vijg J, Sugarbaker DJ, Corson JM and Fletcher JA: Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11: 511-515, 1995.
5. INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 16(24): 3087-3095, 1998.
6. INK4a adenovirus. Cancer Gene Ther 7(11): 1421-1425, 2000.
7. Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F et al: Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 92(8): 636-641, 2000.
8. Giuliano M, Catalano A, Strizzi L, Vianale G, Capogrossi M and Procopio A: Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med 5(6): 591-596, 2000.
9. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA et al: Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4(12): 1449-1452, 1998.
10. Vives E, Richard JP, Rispal C and Lebleu B: TAT peptide internalization: seeking the mechanism of entry. Curr Protein Pept Sci 4(2): 125-132, 2003.
11. Leifert JA, Harkins S and Whitton JL: Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther 9(21): 1422-1428, 2002.
12. Ho A, Schwarze SR, Mermelstein SJ, Waksman G and Dowdy SF: Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 61(2): 474-477, 2001.
13. Pass HI and Mew DJ: In vitro and in vivo studies of mesothelioma. J Cell Biochem Suppl 24(142): 142-151, 1996.
14. INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. Cancer Res 59(11): 2577-2580, 1999.
15. Kratzke RA, Otterson GA, Lin AY, Shimizu E, Alexandrova N, Zajac-Kaye M et al: Functional analysis at the Cys706 residue of the retinoblastoma protein. J Biol Chem 267(36): 25998-26003, 1992.
16. Kaelin W Jr, Ewen ME and Livingston DM: Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product. Mol Cell Biol 10(7): 3761-3769, 1990.
17. Mayo KH, Dings RP, Flader C, Nesmelova I, Hargittai B, van der Schaft DW et al: Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem 278(46): 45746-45752, 2003.
18. Kaye FJ, Kratzke RA, Gerster JL and Horowitz JM: A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc Natl Acad Sci USA 87(17): 6922-6926, 1990.